Teva Pharmaceutical Industries has launched the first generic version of Sandostatin LAR Depot in the U.S., offering a more affordable treatment option for patients with acromegaly and severe diarrhea associated with carcinoid syndrome. The launch comes amidst potential market impacts related to recent events in the Middle East.
The U.S. Supreme Court has declined to review Vanda Pharmaceuticals’ attempt to revive patents for its sleep-disorder medication Hetlioz. The Federal Circuit had invalidated the patents in a legal battle with generic drugmakers Teva Pharmaceutical Industries and Apotex. The decision marks the Supreme Court’s avoidance of addressing when a patent can be invalidated as “obvious” since 2007.
